Business
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.
About this update from Sk Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise.","length":209,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":341,"olType":false},{"type":"text","content":"SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.","length":295,"tagName":"p"},{"type":"image","alt":"Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.","displaySize":"","headline":null,"caption":"Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":301,"url":"https://media.zenfs.com/en/prnewswire.com/24db0c13874e215329456a81ee9b4542"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z7TJScHWoebr.K82Qh...